Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See why I rate PFE stock as a Hold.

Aamir Malik; Executive Vice President, Chief US Commercial Officer; Pfizer Inc Andrew Baum; Chief Strategy and Innovation Officer, Executive Vice President; Pfizer Inc Alexandre De Germay; Executive ...

Pfizer’s PFE fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago ...

The fund’s new buys during the fourth quarter included, by size of position, Kenvue (KVUE), Pfizer (PFE), Healthcare Realty Trust (HR), iShares Core S&P Mid-Cap ETF (IJH), and Riot Platforms (RIOT).

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...